AnaptysBio (NASDAQ:ANAB) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of AnaptysBio (NASDAQ:ANAB) from a hold rating to a sell rating in a research note published on Tuesday, Zacks.com reports.

According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “

Several other brokerages have also issued reports on ANAB. HC Wainwright set a $126.00 price objective on shares of AnaptysBio and gave the company a buy rating in a report on Monday, June 24th. Credit Suisse Group cut their price objective on shares of from GBX 145 ($1.89) to GBX 105 ($1.37) and set a neutral rating on the stock in a report on Friday, June 21st. Stifel Nicolaus lowered shares of AnaptysBio from a buy rating to a hold rating and cut their price objective for the company from $124.00 to $74.00 in a report on Friday, June 21st. Cantor Fitzgerald lifted their price objective on shares of Horizon Therapeutics from $26.00 to $32.00 and gave the company a buy rating in a report on Tuesday, April 2nd. Finally, SunTrust Banks reissued a buy rating and set a $35.00 price objective on shares of Whiting Petroleum in a report on Monday, June 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $111.25.

Shares of ANAB stock opened at $54.11 on Tuesday. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of -21.64 and a beta of 1.38. The company’s 50 day simple moving average is $65.49. AnaptysBio has a 52-week low of $52.71 and a 52-week high of $110.00.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.83) by $0.01. Equities research analysts forecast that AnaptysBio will post -3.76 EPS for the current fiscal year.

In other news, insider Marco Londei sold 10,060 shares of AnaptysBio stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $73.06, for a total transaction of $734,983.60. Following the completion of the sale, the insider now directly owns 32,437 shares in the company, valued at $2,369,847.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Hamza Suria sold 22,428 shares of AnaptysBio stock in a transaction on Monday, June 10th. The stock was sold at an average price of $73.76, for a total transaction of $1,654,289.28. Following the sale, the chief executive officer now owns 31,524 shares of the company’s stock, valued at $2,325,210.24. The disclosure for this sale can be found here. 14.00% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the company. Tekla Capital Management LLC increased its holdings in AnaptysBio by 43.4% in the fourth quarter. Tekla Capital Management LLC now owns 65,845 shares of the biotechnology company’s stock valued at $4,200,000 after buying an additional 19,935 shares in the last quarter. FMR LLC increased its holdings in AnaptysBio by 2.0% in the fourth quarter. FMR LLC now owns 4,012,735 shares of the biotechnology company’s stock valued at $255,973,000 after buying an additional 77,268 shares in the last quarter. TD Asset Management Inc. increased its holdings in AnaptysBio by 45.4% in the first quarter. TD Asset Management Inc. now owns 20,509 shares of the biotechnology company’s stock valued at $1,498,000 after buying an additional 6,400 shares in the last quarter. Millennium Management LLC increased its stake in shares of AnaptysBio by 11,829.2% during the fourth quarter. Millennium Management LLC now owns 258,624 shares of the biotechnology company’s stock worth $16,498,000 after purchasing an additional 256,456 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in shares of AnaptysBio by 94.6% during the fourth quarter. Deutsche Bank AG now owns 74,864 shares of the biotechnology company’s stock worth $4,774,000 after purchasing an additional 36,395 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

Featured Article: Do investors pay a separate front-end load every time they buy additional shares?

Get a free copy of the Zacks research report on AnaptysBio (ANAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit